Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

grazoprevir

- PMLiVE

First Merck/Samsung biosimilar cleared in South Korea

Approval of Brenzys further opens up competition in biosimilar market

- PMLiVE

NICE hands Merck & Co’s Keytruda speedy recommendation

Cancer drug backed for NHS use against advanced melanoma

- PMLiVE

First-ever World Hepatitis Summit calls for national programmes

Follows rise in hepatitis deaths for fifth consecutive year

Merck & Co expands board and adds new directors

Appoints Dr Paul Rothman and Pamela Craig

- PMLiVE

David Khougazian appointed president of Sanofi Pasteur MSD

He will succeed Dr Jean-Paul Kress atthe Sanofi Pasteur - Merck & Co venture

Roche Basel Switzerland

Roche’s breakthrough PD-L1 drug slows cancer growth

Latest positive trial for the firm’s next-gen oncology product atezolizumab

Allergan logo

Allergan stumps up $375m for bolt-on acquisitions

Firm has recently added two migraine drugs and Oculeve to its portfolio

- PMLiVE

Opdivo approved via UK’s early drug access scheme

Bristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

- PMLiVE

Merck files all-oral hepatitis C therapy in US

Seeking approval for grazoprevir and elbasvir, which already has FDA breakthrough status

- PMLiVE

AbbVie remains top of immunology sales

But the threat of biosimilars once again threatens to shake up the leader board

- PMLiVE

Relief as study finds no cardiovascular risk with Januvia

FDA continues to investigate safety of numerous diabetes therapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links